Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 4, 2015

Primary Completion Date

April 24, 2015

Study Completion Date

April 24, 2015

Conditions
Healthy
Interventions
DRUG

Formulation A

Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

DRUG

Formulation B

10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

DRUG

Formulation C

10 mg/mL oral solution containing 10 mg/mL sucralose.

DRUG

Formulation D

10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.

DRUG

Formulation E

10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.

DRUG

Formulation F

10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

DRUG

Formulation M1

Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation M2

Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation M3

Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation N1

Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation N2

Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation N3

Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Trial Locations (1)

Unknown

Nottingham

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT02426632 - Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants | Biotech Hunter | Biotech Hunter